Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Green JB, et al. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. N Engl J Med. 2015. PMID: 26052984 Free article. Clinical Trial.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
Safety of Insulin Degludec/Insulin Aspart in Patients with Diabetes Mellitus over a Period of 1 Year during Routine Clinical Care in India: SMART (Study of Management of Diabetes with Ryzodeg™ Treatment).
Kesavadev J, Gowda A, Kumar H, Yalamanchi SR, Lodha S, Singh KP, Basu D, Asirvatham A, Shah N, Pathan MK, Revanna M, Mukherjee JJ. Kesavadev J, et al. Med Sci (Basel). 2021 Dec 21;10(1):1. doi: 10.3390/medsci10010001. Med Sci (Basel). 2021. PMID: 35076540 Free PMC article.
Fixed-Dose Combination of Canagliflozin and Metformin as an Adjunct to Diet and Exercise in Indian Adults with Type 2 Diabetes Mellitus: Results from a Multicentric, Open-Label, Single-Arm, Phase IV Study.
Magdum M, Unnikrishnan AG, Farishta F, Balamurugan R, Murthy S, Desai P, Singh KP, Barauh M, Rastogi A, Kesavadev J, Lakhani P, Panchal S, Korde T, Acharya R, Dixit J. Magdum M, et al. Among authors: kesavadev j. J Assoc Physicians India. 2024 Apr;72(4):13-20. doi: 10.59556/japi.72.0488. J Assoc Physicians India. 2024. PMID: 38881077 Clinical Trial.
One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India-TRUST (Tresiba real-world use study).
Kesavadev J, Murthy LS, Chaudhury T, Yalamanchi SR, Giri J, Gupta S, Phatak S, Modi KD, Chatterjee S, Manjunath A, Revanna M, Bhattacharya A. Kesavadev J, et al. Metabol Open. 2022 Apr 18;14:100184. doi: 10.1016/j.metop.2022.100184. eCollection 2022 Jun. Metabol Open. 2022. PMID: 35496980 Free PMC article.
97 results